visudyne
cheplapharm arzneimittel gmbh - verteporfina - myopia, degenerative; macular degeneration - oftalmológicos - visudyne está indicado para el tratamiento de:adultos con exudativa (húmedo) relacionada con la edad degeneración macular (amd) con predominantemente clásica subfoveales la neovascularización coroidea (nvc) o;adultos con subfoveales la neovascularización coroidea secundaria a miopía patológica.
visudyne®
nippon fine chemical co. ltd. (nfc) - verteporfina - polvo liofilizado para solución para infusión iv - 15 mg
visudyne
1-nippon fine chemical co. ltd. (nfc), hyogo, japon. (producto intermedio) 2- jhp pharmaceuticals lcc, michigan, estados unidos - verteporfina - polvo liofilizado para solución para infusión iv. - 15 mg
lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmológicos - lucentis está indicado en adultos para:el tratamiento de glaucoma (húmedo) relacionada con la edad degeneración macular (amd)el tratamiento de la discapacidad visual, debido a la neovascularización coroidea (nvc)el tratamiento de la discapacidad visual debido a edema macular diabético (dme)el tratamiento de la discapacidad visual, debido a que el edema macular secundario a la oclusión venosa retiniana (rama rvo o central rvo).
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmológicos - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
visudyne 15 mg iv 1 vial pols per solució
lucentis 10 mg/ml 1 vial solució injectables + 1 agulla
lucentis 10 mg/ml 1 xeringa precarregada